Hemoglobin synthesis enzyme system

The hemoglobin synthesis enzyme system encompasses the coordinated enzymatic pathways for globin chain production and heme biosynthesis, primarily in erythroid precursors of the bone marrow. Heme synthesis involves eight enzymes operating between mitochondria and cytosol, starting with the rate-limiting condensation of glycine and succinyl-CoA to form δ-aminolevulinic acid (ALA) by ALA synthase (ALAS2 in erythroid cells), followed by steps including ALA dehydratase, porphobilinogen deaminase, uroporphyrinogen decarboxylase, coproporphyrinogen oxidase, protoporphyrinogen oxidase, and ferrochelatase to insert iron into protoporphyrin IX.[1][2][3] Globin synthesis occurs via transcription and translation of alpha (chromosome 16) and beta (chromosome 11) chains in the cytosol, induced by heme availability to ensure balanced hemoglobin tetramer assembly.[1][2] Heme regulates its own synthesis, globin translation via heme-regulated inhibitor (HRI), and erythroid differentiation through factors like GATA1 and iron-responsive elements.[3][4] Dysregulation leads to porphyrias from intermediate accumulation (e.g., acute intermittent porphyria from porphobilinogen deaminase deficiency) or sideroblastic anemia from ALAS2 or ferrochelatase defects.[3][5] While essential for oxygen transport, therapeutic targeting is rare due to toxicity risks from pathway disruption, though drugs inducing cytochrome P450 can dysregulate hepatic ALAS1.[3] This system is not a single molecular target but a multi-enzyme pathway, complicating direct drug modulation.[1][3][4] ## Notes on is_incorrect: true The provided name "Hemoglobin synthesis enzyme system" is overly broad and not a specific therapeutic target like a single receptor, enzyme, or protein; it refers to an entire multi-enzyme biosynthetic pathway involving at least 8 heme synthesis enzymes plus globin translation machinery, lacking a unified canonical entity in standard databases like UniProt or drug target lists.[1][2][3] Specific enzymes (e.g., ALAS2, ferrochelatase) are individually studied in diseases but not collectively as one "system" for drug targeting.[3][4][5]

Other names

Heme biosynthetic pathwayHeme synthesis pathwayErythroid heme synthesis enzymes